Howard B. Lieberman, Ph.D.
Professor of Radiation Oncology
Professor of Environmental Health Sciences
Department of Radiation Oncology, Center for Radiological Research
Dept. Environmental Health Sciences, Mailman School of Public Health
Center for Radiological Research
630 West 168th Street
New York, NY 10032
Telephone: (212) 305-9241
Fax: (212) 305-3229
BS, Brooklyn College, 1977
PhD, Rutgers University, 1982
Postdoctoral Fellow, Yale University, 1986
My laboratory is devoted to understanding molecular aspects of radioresistance, chemoresistance and regulation of cell cycle progression in human, mouse and yeast cells. We are especially interested in understanding mechanisms of carcinogenesis and the basis for radiation-induced bystander effects; that is the phenomenon where cells neighboring those directly “hit” by radiation demonstrate phenotypes similar to irradiated cells. We focus on the role of the evolutionarily conserved, multifunctional gene called Rad9 in these processes.
Member, Radiation Therapeutics and Biology Study Section, NIH, 2011-present
Associate Editor, Radiation Research, 2009-present
Associate Editor, Journal of Cellular Physiology, 2006-present
Member, Israel Cancer Research Fund Scientific Advisory Board, 2002-present
External reviewer, Joint Center for Radiation Therapy Foundation, Harvard Medical School, 2001-present
Member, NCI Initial Review Group Basic and Preclinical Subcommittee C, 2000-2005
Member (1995-2000), Chairman (1998-2000), Radiation Study Section, NIH
Broustas CG, Lieberman HB. Contributions of Rad9 to tumorigenesis. J Cell Biochem 113, 742-751, 2012.
Lieberman HB, Bernstock JD, Broustas CG, Hopkins KM, Leloup C, Zhu A. The role of RAD9 in tumorigenesis. J Mol Cell Biol 3, 39-43, 2011.
Leloup C, Hopkins KM, Wang X, Zhu A, Wolgemuth DJ, Lieberman HB. Mouse Rad9b is essential for embryonic development and promotes resistance to DNA damage. Dev Dyn 239, 2837-2850, 2010.
Han L, Hu Z, Liu Y, Wang X, Hopkins KM, Lieberman HB, Hang H. Mouse Rad1 deletion enhances susceptibility for skin tumor development. Mol Cancer 9, 67, 2010.
Hei TK, Zhou H, Ivanov VN, Hong M, Lieberman HB, Brenner DJ, Amundson SA, Geard CR. Mechanism of Radiation-Induced Bystander Effects: A Unifying Model. J Pharmacy Pharmacol 60, 943-950, 2008.
Hu Z, Liu Y, Zhang C, Zhao Y, He W, Han L, Yang L, Hopkins KM, Yang X, Lieberman HB, Hang H. Targeted deletion of Rad9 in mouse skin keratinocytes enhances genotoxin-induced tumor development. Cancer Res 68, 5552-5561, 2008.
Lieberman HB. DNA damage repair and response proteins as targets for cancer therapy. Curr Med Chem 15, 360-367, 2008.
Zhu A, Zhang CX, Lieberman HB. Rad9 has a functional role in human prostate carcinogenesis. Cancer Res 68, 1267-1274, 2008.
Liu YX, Wang J, Guo J, Wu J, Lieberman HB, Yin Y. DUSP1 Is Controlled by p53 during the Cellular Response to Oxidative Stress. Mol Cancer Res 6, 624-633, 2008.
Kleiman NJ, David J, Elliston CD, Hopkins KM, Smilenov LB, Brenner DJ, Worgul BV, Hall EJ, Lieberman HB. Mrad9 and atm haploinsufficiency enhance spontaneous and X-ray-induced cataractogenesis in mice. Radiat Res 168, 567-573, 2007.
Honors and Awards
Distinguished Alumnus Award, The Lay Advocate Program of Brooklyn College, 2007
Elected Fellow, American Association for the Advancement of Science, 2006
NIH Research Career Development Award, 2005
Elliot Osserman Award, Israel Cancer Research Fund, for Distinguished Service, 2002
HOSA Distinguished Service Award - Health Occupations Students of America, 1993